131 related articles for article (PubMed ID: 6126231)
1. The relationship between plasma and red blood cell neuroleptic levels, oral dosage, and clinical parameters in a chronic schizophrenic population.
Dunlop SR; Shea PA; Hendrie HC
Biol Psychiatry; 1982 Aug; 17(8):929-36. PubMed ID: 6126231
[TBL] [Abstract][Full Text] [Related]
2. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
4. Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients.
Lindenmayer JP; Smith D; Katz I
J Clin Psychiatry; 1984 Mar; 45(3):117-9. PubMed ID: 6142035
[TBL] [Abstract][Full Text] [Related]
5. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH
Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524
[TBL] [Abstract][Full Text] [Related]
6. Plasma drug and homovanillic acid levels in psychotic patients receiving neuroleptics.
Harris PQ; Brown SJ; Friedman MJ; Bacopoulos NG
Biol Psychiatry; 1984 Jun; 19(6):849-60. PubMed ID: 6146355
[TBL] [Abstract][Full Text] [Related]
7. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
Contreras S; Alexander H; Faber R; Bowden C
J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
[TBL] [Abstract][Full Text] [Related]
9. Neuroleptic-refractory patients and their drug plasma levels.
Berrios GE
Encephale; 1982; 8(4):465-85. PubMed ID: 6129961
[TBL] [Abstract][Full Text] [Related]
10. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
[TBL] [Abstract][Full Text] [Related]
11. Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
Greenberg JS; Brown WA; Laughren TP; Krantz J
Psychopharmacol Bull; 1983; 19(1):74-6. PubMed ID: 6131470
[No Abstract] [Full Text] [Related]
12. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.
Shvartsburd A; Sajadi C; Morton V; Mirabi M; Gordon J; Smith RC
J Clin Psychopharmacol; 1984 Aug; 4(4):194-8. PubMed ID: 6470190
[TBL] [Abstract][Full Text] [Related]
13. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
[TBL] [Abstract][Full Text] [Related]
14. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine.
Garver DL; Dekirmenjian H; Davis JM; Casper R; Ericksen S
Am J Psychiatry; 1977 Mar; 134(3):304-7. PubMed ID: 14514
[TBL] [Abstract][Full Text] [Related]
15. Haloperidol plasma and red blood cell levels and clinical antipsychotic response.
Garver DL; Hirschowitz J; Glicksteen GA; Kanter DR; Mavroidis ML
J Clin Psychopharmacol; 1984 Jun; 4(3):133-7. PubMed ID: 6736272
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations of timiperone and its reduced metabolite in the patients on timiperone.
Shimoda K; Someya T; Morita S; Hirokane G; Yokono A; Shibasaki M; Takahashi S
Psychiatry Clin Neurosci; 1998 Oct; 52(5):535-40. PubMed ID: 10215017
[TBL] [Abstract][Full Text] [Related]
17. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
Young AS; Faraone SV; Brown WA
J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
[TBL] [Abstract][Full Text] [Related]
18. Blood levels of haloperidol in schizophrenic patients.
Shvartsburd A; Dekirmenjian H; Smith RC
J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
[TBL] [Abstract][Full Text] [Related]
19. Plasma amisulpride levels in schizophrenia or schizoaffective disorder.
Bergemann N; Kopitz J; Kress KR; Frick A
Eur Neuropsychopharmacol; 2004 May; 14(3):245-50. PubMed ID: 15056484
[TBL] [Abstract][Full Text] [Related]
20. Schizophrenic thinking and neuroleptic dosage.
Puente AE; Andersson C
J Clin Psychol; 1987 Mar; 43(2):189-97. PubMed ID: 2883201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
